Results 211 to 220 of about 16,235 (248)
Search for Specific Inhibitors Targeting Type IA Topoisomerases. [PDF]
Chadni SH, Ferdous S, Tse-Dinh YC.
europepmc +1 more source
Ischaemic stroke is characterised by acute cerebrovascular occlusion and blood–brain barrier (BBB) breakdown. Our results indicated that the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) ameliorated the loss of BBB integrity, changed the morphology of brain endothelial cells, increased the level of basement membrane and ...
Anikó Szecskó +14 more
wiley +1 more source
Molecular Determinants of Response and Rational Drug Combinations for Antibody-Drug Conjugates (ADCs) with Topoisomerase I (TOP1) Inhibitor Payloads. [PDF]
Pommier Y.
europepmc +1 more source
Clonal Hematopoiesis and CAR T Cell Therapy: From Biological Crosstalk to Clinical Implications
ABSTRACT Clonal hematopoiesis (CH) is increasingly recognized as a significant biological phenomenon in aging and cancer, marked by the expansion of hematopoietic stem and progenitor cells harboring somatic mutations in genes associated with myeloid neoplasms.
Wei Du +4 more
wiley +1 more source
DNA topological regulation in RNA polymerase II transcription. [PDF]
Bunch H.
europepmc +1 more source
Organelle‐Resolved Tetrazine‐trans‐Cyclooctene Click Chemistry for Cargo Delivery and Release
Bioorthogonal click chemistry tools provide a means for specific intracellular conjugation of molecules. In this study, we used reactive tetrazine (Tz) and TCO moieties for labeling of organelles and organelle‐specific delivery and activation of doxorubicin prodrugs.
Oleh Durydivka +6 more
wiley +1 more source
Novel Bacterial Topoisomerase Inhibitors: A New Front in an Old War. [PDF]
Mann CA, Dewar JM, Osheroff N.
europepmc +1 more source
The evolving role of immunotherapy in ovarian cancer
Abstract Ovarian cancer remains a major cause of gynecologic cancer mortality; and, although immune checkpoint inhibitors have transformed treatment in other solid tumors, their activity in ovarian cancer has been limited by tumor heterogeneity, an immunosuppressive tumor microenvironment, and the lack of robust predictive biomarkers.
Ana Carolina Veneziani +2 more
wiley +1 more source
Enzyme-DNA Interactions Affect the Catalytic Inhibition of Mycobacterial Gyrases by Antibacterial Drugs. [PDF]
Armenia JF, Osheroff N.
europepmc +1 more source

